Randomized, Double-blind, Placebo Controlled, Clinical Trial of the Immunogenicity, Safety, and Efficacy of the Gam-COVID-Vac Combined Vector Vaccine in Prophylactic Treatment for SARS-СoV-2 Infection
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Covid19
- Sponsor
- Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
- Enrollment
- 2000
- Primary Endpoint
- Seroconversion rate
- Last Updated
- 5 years ago
Overview
Brief Summary
Randomized, double-blind, placebo controlled clinical trial of immunogenicity, safety and efficacy of the Gam-COVID-Vac combined vector vaccine against the SARS-CoV-2-induced coronavirus infection in adults.
Detailed Description
Randomized, double-blind (blinded for trial subject and the study physician), placebo controlled clinical trial in parallel assignment of the immunogenicity, safety, and efficacy of the Gam-COVID-Vac combined vector vaccine against the SARS-CoV-2-induced coronavirus infection in adults. The trial will include 2,000 volunteers over the age of 18. After screening, they will be randomised (3:1) into two groups - a reference group of 500 volunteers who will receive the placebo and a study group of 1,500 volunteers who will receive the combined Gam-COVID-Vac vaccine against SARS-induced coronavirus infection-СoV-2oV-2. The trial subjects will be randomized into five age strata: 18-30, 31-40, 41-50, 51-60 and 60+ years. Each subject will participate in the trial for 180±14 days after the first dose of the study drug/placebo and will have one screening visit and five on-site visits to the study physician during the said period. The study drug/placebo will be administered intramuscularly during vaccination visits 1 and 2 (day 1 and day 21±2). Follow-up visits Nos. 3, 4, 5 will be conducted on days 28±2, 42±2 and 180±14, respectively. Blood samples will be taken from certain subjects during the following visits to assess the immunogenicity parameters on days 1, 42±2 and 180±14. During observation visits, vital indicators will be assessed on all trial subjects and changes in the subjects' condition and well-being will be recorded, observational visits may be remote, using telemedicine (TM) technologies. Additionally, the trial subjects will be able to have remote consultations with the study physician through the TM. Data from trial subjects will be collected through electronic case report forms.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Written informed consent of a subject to participate in the trial
- •Males and females aged 18+
- •Negative HIV, hepatitis, and syphilis test results
- •A negative test result for the presence of IgM and IgG antibodies to SARS CoV2 by enzyme immunoassay
- •A negative test result for COVID-2019 by PCR at screening visit
- •No COVID-2019 in the medical history
- •No contact with COVID-2019 persons within at least 14 days before the enrollment (according to trial subjects)
- •Consent to use effective contraception methods during the trial
- •Negative urine pregnancy test at the screening visit (for child-bearing age women)
- •Negative drugs or psychostimulants urine test at the screening visit
Exclusion Criteria
- •Any vaccination/immunization within 30 days before the enrollment;
- •Steroids (except hormonal contraceptives) and/or immunoglobulins or other blood products therapy not finished 30 days before the enrollment.
- •Immunosuppressors therapy finished within 3 months before the enrollment
- •Pregnancy or breast-feeding
- •Acute coronary syndrome or stroke suffered less than one year before the enrollment
- •Tuberculosis, chronic systemic infections
- •Drug allergy (anaphylactic shock, Quincke's edema, polymorphic exudative eczema, atopy, serum disease), hypersensitivity or allergic reaction to immunobiological products, known allergic reactions to study drug components, acute exacerbation of allergic diseases on the enrollment day
- •Neoplasms in the medical history.
- •Donated blood or plasma (450+ ml) within 2 months before the enrollment
- •Splenectomy in the medical history
Outcomes
Primary Outcomes
Seroconversion rate
Time Frame: 42 day, 180 day
Percentage of trial subjects with fourfold or more increase in the titer of SARS-CoV-2 glycoprotein-specific antibodies in 2,000 trial subjects on the drug administration day before injecting the first dose of the study drug/placebo and 42±2 and 180±14 days after the first dose
Secondary Outcomes
- Percentage of trial subjects with coronavirus disease 2019 (COVID-19)(through the study (till day 180))
- Incidence and severity of adverse events(through the study (till day 180))
- Virus-neutralizing antibody levels against the SARS-CoV-2(42 day)
- Antibody levels against the SARS-CoV-2 glycoprotein(42 day, 180 day)